Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
BRAF V600E + RNF43 mutation
i
Other names:
BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1, RNF43, Ring Finger Protein 43, RING-Type E3 Ubiquitin Transferase RNF43, E3 Ubiquitin-Protein Ligase RNF43, RING Finger Protein 43, EC 2.3.2.27, RNF124
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
673
;
54894
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
BRAF V600E + RNF43 mutation
Colorectal Cancer
BRAF V600E + RNF43 mutation
Colorectal Cancer
cetuximab + encorafenib
Sensitive: C3 – Early Trials
cetuximab + encorafenib
Sensitive
:
C3
cetuximab + encorafenib
Sensitive: C3 – Early Trials
cetuximab + encorafenib
Sensitive
:
C3
BRAF V600E + RNF43 mutation
Colorectal Cancer
BRAF V600E + RNF43 mutation
Colorectal Cancer
cetuximab + trametinib + dabrafenib
Sensitive: C3 – Early Trials
cetuximab + trametinib + dabrafenib
Sensitive
:
C3
cetuximab + trametinib + dabrafenib
Sensitive: C3 – Early Trials
cetuximab + trametinib + dabrafenib
Sensitive
:
C3
BRAF V600E + RNF43 mutation
Colorectal Cancer
BRAF V600E + RNF43 mutation
Colorectal Cancer
cetuximab + trametinib + vemurafenib
Sensitive: C3 – Early Trials
cetuximab + trametinib + vemurafenib
Sensitive
:
C3
cetuximab + trametinib + vemurafenib
Sensitive: C3 – Early Trials
cetuximab + trametinib + vemurafenib
Sensitive
:
C3
BRAF V600E + RNF43 mutation
Colorectal Cancer
BRAF V600E + RNF43 mutation
Colorectal Cancer
cetuximab + vemurafenib
Sensitive: C3 – Early Trials
cetuximab + vemurafenib
Sensitive
:
C3
cetuximab + vemurafenib
Sensitive: C3 – Early Trials
cetuximab + vemurafenib
Sensitive
:
C3
BRAF V600E + RNF43 mutation
Colorectal Cancer
BRAF V600E + RNF43 mutation
Colorectal Cancer
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFR inhibitor
Sensitive
:
C3
EGFR inhibitor
Sensitive: C3 – Early Trials
EGFR inhibitor
Sensitive
:
C3
BRAF V600E + RNF43 mutation
Colorectal Cancer
BRAF V600E + RNF43 mutation
Colorectal Cancer
BRAF inhibitor
Sensitive: C3 – Early Trials
BRAF inhibitor
Sensitive
:
C3
BRAF inhibitor
Sensitive: C3 – Early Trials
BRAF inhibitor
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login